 HOUSTON, July 26, 2021 GLOBE NEWSWIRE -- Bellicum Pharmaceuticals, Inc. NASDAQ:BLCM, a leader in developing novel, controllable cellular immunotherapies for cancers, today announced an equity inducement grant to one new employee consisting of an aggregate of 15,000 stock options. The Compensation Committee of the Board of Directors approved the grant with an effective date of July 26, 2021. The stock options were granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635c4. 